SCHEMBL8964192

SCHEMBL8964192

COc1cccc(CCl)c1Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
MAPT P10636 10/20 0.47
LMNA P02545 4/20 0.47
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HSPB1 P04792 2/20 0.44
HTR1A P08908 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
PKM P14618 2/20 0.43
GAA P10253 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8964199 0.87 ALDH1A1 (0.53) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL4387499 0.80 HTT (0.53) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL8875770 0.79 ALDH1A1 (0.48) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL8875765 0.79 ALDH1A1 (0.48) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL8875762 0.79 ALDH1A1 (0.48) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL8964023 0.77 ALDH1A1 (0.54) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL8964205 0.77 ALDH1A1 (0.48) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL5082634 0.75 ALDH1A1 (0.66) ALDH1A1MAPTHPGDSMN1; SMN2HSPB1
SCHEMBL8432682 0.75 ALDH1A1 (0.49) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL2500056 0.73 SMN1; SMN2 (0.50) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5525614-A TREATING VASCULAR RESTENOSIS, CNS DISORDERS WARNER-LAMBERT COMPANY (US) 1996-06-11 US disclosed
US-5489686-A CARDIOVASCULAR DISORDER, NERVOUS SYSTEM DISORDER, ANTIDIURETIC , PSYCHLOGICAL DISORDER, ANTIDEPRESSANTS WARNER-LAMBERT COMPANY (US) 1996-02-06 US disclosed
EP-0641326-A1 SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES WARNER-LAMBERT COMPANY (US) 1995-03-08 EP disclosed
US-5350757-A Treatment of vascular restenosis, nervous system disorders and cognition enhancement WARNER-LAMBERT COMPANY (US) 1994-09-27 US disclosed
WO-1993023378-A1 SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES WARNER-LAMBERT COMPANY (US) 1993-11-25 WO disclosed
US-5246943-A Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties WARNER-LAMBERT COMPANY (US) 1993-09-21 US disclosed